Cardiff Oncology Inc (CRDF)

NASDAQ
Currency in USD
4.575
+0.285(+6.64%)
Real-time Data
CRDF Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 9 days
Fair Value
Day's Range
4.4554.729
52 wk Range
1.6506.420
Key Statistics
Edit
Prev. Close
4.29
Open
4.5
Day's Range
4.455-4.729
52 wk Range
1.65-6.42
Volume
370.94K
Average Vol. (3m)
2.06M
1-Year Change
147.98%
Book Value / Share
1.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRDF Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.750
Upside
+134.97%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Cardiff Oncology Inc Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Compare CRDF to Peers and Sector

Metrics to compare
CRDF
Peers
Sector
Relationship
P/E Ratio
−7.0x−4.6x−0.7x
PEG Ratio
1.83−0.070.00
Price / Book
6.1x2.2x2.6x
Price / LTM Sales
440.1x12.0x3.1x
Upside (Analyst Target)
133.1%265.2%47.6%
Fair Value Upside
Unlock−1.1%7.7%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.750
(+134.97% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.25 / -0.27
Revenue / Forecast
165.00K / 80.00K
EPS Revisions
Last 90 days

People Also Watch

1.849
PLBY
-5.16%
3.975
BLDE
+6.00%
16.52
OSCR
+22.77%
2.010
QSI
+3.08%
3.750
ATYR
+9.97%

FAQ

What Is the Cardiff Oncology (CRDF) Stock Price Today?

The Cardiff Oncology stock price today is 4.575

What Stock Exchange Does Cardiff Oncology Trade On?

Cardiff Oncology is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Cardiff Oncology?

The stock symbol for Cardiff Oncology is "CRDF."

What Is the Cardiff Oncology Market Cap?

As of today, Cardiff Oncology market cap is 303.42M.

What is Cardiff Oncology Earnings Per Share?

The Cardiff Oncology EPS is -0.95.

What Is the Next Cardiff Oncology Earnings Date?

Cardiff Oncology will release its next earnings report on Feb 27, 2025.

From a Technical Analysis Perspective, Is CRDF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.